[go: up one dir, main page]

AR017976A1 - Forma de dosis sublingual para mejorar la disfuncion sexual en una mujer - Google Patents

Forma de dosis sublingual para mejorar la disfuncion sexual en una mujer

Info

Publication number
AR017976A1
AR017976A1 ARP990100389A ARP990100389A AR017976A1 AR 017976 A1 AR017976 A1 AR 017976A1 AR P990100389 A ARP990100389 A AR P990100389A AR P990100389 A ARP990100389 A AR P990100389A AR 017976 A1 AR017976 A1 AR 017976A1
Authority
AR
Argentina
Prior art keywords
woman
dose form
administered
apomorphine
sublingual dose
Prior art date
Application number
ARP990100389A
Other languages
English (en)
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of AR017976A1 publication Critical patent/AR017976A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La forma de dosis sublingual para mejorar la disfuncion sexual en una mujer comprende apomorfina o una sal de adicion de ácido farmacéuticamenteaceptable de la misma, que al ser administrada a dicha mujer se incrementa el flujo sanguíneo intraclitoral y el flujo sanguíneo de la pared vaginalpor la estimulacion de dicha mujer, pero menos que la cantidad que induce nauseas sustanciales. La forma de dosis sublingual para estimular losreceptores de la dopamina en la region mesocefálica de una mujercon el fin de provocar la erectogénesis del clítoris y un agrandamiento vaginalcuando se administra a la mujer, contiene entre aproximadamente 25 y aproximadamente 80 microgramos de apomorfina por kilogramo de peso corporal yse administra a una velocidad suficiente para mantener una concentracion en plasma de la apomorfina de o más de 5,5 nanogramos por mililitro durante laactividad sexual.
ARP990100389A 1998-01-30 1999-01-29 Forma de dosis sublingual para mejorar la disfuncion sexual en una mujer AR017976A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/016,252 US5945117A (en) 1998-01-30 1998-01-30 Treatment of female sexual dysfunction

Publications (1)

Publication Number Publication Date
AR017976A1 true AR017976A1 (es) 2001-10-24

Family

ID=21776169

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100389A AR017976A1 (es) 1998-01-30 1999-01-29 Forma de dosis sublingual para mejorar la disfuncion sexual en una mujer

Country Status (34)

Country Link
US (2) US5945117A (es)
EP (1) EP1056419A4 (es)
JP (1) JP2002501875A (es)
KR (1) KR20010040477A (es)
CN (1) CN1250221C (es)
AR (1) AR017976A1 (es)
AU (1) AU752928B2 (es)
BG (1) BG64667B1 (es)
BR (1) BR9908038A (es)
CA (1) CA2322289A1 (es)
CO (1) CO4970819A1 (es)
CR (1) CR5959A (es)
DZ (1) DZ2714A1 (es)
GC (1) GC0000096A (es)
GT (1) GT199900013A (es)
HK (1) HK1040901B (es)
HN (1) HN1999000015A (es)
HU (1) HUP0101268A3 (es)
IL (2) IL137569A0 (es)
JO (1) JO2085B1 (es)
MA (1) MA26600A1 (es)
MX (1) MXPA00007447A (es)
NO (1) NO319821B1 (es)
NZ (1) NZ506597A (es)
PA (1) PA8467801A1 (es)
PE (1) PE20000240A1 (es)
PL (1) PL194350B1 (es)
SK (1) SK11362000A3 (es)
TN (1) TNSN99008A1 (es)
TR (1) TR200002220T2 (es)
TW (1) TW550069B (es)
UY (1) UY25374A1 (es)
WO (1) WO1999038467A1 (es)
ZA (1) ZA99686B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
AU4254799A (en) * 1998-06-22 2000-01-10 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050245494A1 (en) * 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20050070499A1 (en) * 1999-11-08 2005-03-31 Pfizer Inc. Compounds for the treatment of female sexual dysfunction
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
WO2001076602A1 (en) 2000-04-07 2001-10-18 Tap Pharmaceutical Products Inc. Apomorphine derivatives and methods for their use
WO2001085013A2 (en) 2000-05-09 2001-11-15 Nitromed, Inc. Infrared thermography and methods of use
ES2291333T3 (es) 2000-06-27 2008-03-01 Qualilife Pharmaceuticals Inc. Composiciones y metodos para el tratamiento de la respuesta sexual de las mujeres.
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6852323B2 (en) 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
HUP0302436A3 (en) 2000-11-15 2004-10-28 Tap Pharmaceutical Prod Inc Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
UY27031A1 (es) * 2000-11-22 2002-07-31 Abbott Lab Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual
CA2435546A1 (en) * 2001-02-08 2002-08-15 Alice C. Martino Rapid-onset medicament for the treatment of sexual dysfunction
CA2479372A1 (en) * 2002-03-19 2003-10-02 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
US20040138291A1 (en) * 2002-10-10 2004-07-15 Adams Michael A. Treatment of sexual dysfunction
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
WO2006100557A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
WO2006105615A1 (en) * 2005-04-08 2006-10-12 Ozpharma Pty Ltd Buccal delivery system
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
WO2007110868A2 (en) 2006-03-28 2007-10-04 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US7800094B2 (en) * 2007-06-11 2010-09-21 Macronix International Co., Ltd. Resistance memory with tungsten compound and manufacturing
HUE028121T2 (en) * 2009-06-12 2016-11-28 Cynapsus Therapeutics Inc Sublingual apomorphine
WO2011130608A1 (en) * 2010-04-15 2011-10-20 Life Science Enhancement Corporation Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
HUE049349T2 (hu) * 2010-12-16 2020-09-28 Sunovion Pharmaceuticals Inc Szublingvális filmek
US9353067B2 (en) 2011-04-10 2016-05-31 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
WO2016172095A1 (en) 2015-04-21 2016-10-27 Cynapsus Therapeutics, Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
JPH07506823A (ja) * 1992-05-18 1995-07-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 記憶障害，性的機能不全およびパーキンソン氏病の治療のためのインドロン誘導体の使用
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
ATE312609T1 (de) * 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
IL137569A0 (en) 2001-07-24
AU2564499A (en) 1999-08-16
CR5959A (es) 1999-07-28
TNSN99008A1 (fr) 2005-11-10
ZA99686B (en) 1999-07-28
WO1999038467A1 (en) 1999-08-05
HN1999000015A (es) 1999-08-23
NO319821B1 (no) 2005-09-19
IL137569A (en) 2006-08-01
HUP0101268A2 (hu) 2001-09-28
PL342062A1 (en) 2001-05-21
CO4970819A1 (es) 2000-11-07
EP1056419A4 (en) 2007-05-02
TR200002220T2 (tr) 2000-12-21
UY25374A1 (es) 1999-09-27
DZ2714A1 (fr) 2003-09-01
JP2002501875A (ja) 2002-01-22
HK1040901A1 (en) 2002-06-28
US5945117A (en) 1999-08-31
NO20003845D0 (no) 2000-07-27
HUP0101268A3 (en) 2002-12-28
NO20003845L (no) 2000-09-28
MXPA00007447A (es) 2006-01-25
JO2085B1 (en) 2000-05-21
GT199900013A (es) 2001-07-20
US6193992B1 (en) 2001-02-27
PL194350B1 (pl) 2007-05-31
BG64667B1 (bg) 2005-11-30
KR20010040477A (ko) 2001-05-15
TW550069B (en) 2003-09-01
CA2322289A1 (en) 1999-08-05
GC0000096A (en) 2005-06-29
NZ506597A (en) 2003-07-25
PE20000240A1 (es) 2000-03-31
CN1313742A (zh) 2001-09-19
EP1056419A1 (en) 2000-12-06
HK1040901B (zh) 2006-11-24
BR9908038A (pt) 2002-01-02
MA26600A1 (fr) 2004-12-20
SK11362000A3 (sk) 2001-02-12
CN1250221C (zh) 2006-04-12
AU752928B2 (en) 2002-10-03
PA8467801A1 (es) 2000-09-29
BG104715A (bg) 2001-02-28

Similar Documents

Publication Publication Date Title
AR017976A1 (es) Forma de dosis sublingual para mejorar la disfuncion sexual en una mujer
NO20014519D0 (no) Apomorfin- og sildenafilpreparat
PE20010925A1 (es) Compuestos inhibidores del neuropeptido y utiles para el tratamiento de la disfuncion sexual femenina
MX9207402A (es) Dispositivo osmotico para surtir un agente benefico a la cavidad oral.
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
BE2012C040I2 (es)
NZ545130A (en) Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
AU749703B2 (en) Combination therapy for modulating the human sexual response
MXPA02009237A (es) Metodos para tratar la disfuncion sexual con apomorfina, a niveles especificos de concentracion en el plasma.
KR950701922A (ko) 치환된 트리아졸의 설페이트 염, 이를 포함하는 약제학적 조성물 및 치료요법에서의 이의 용도(The sulphate salt of a substituted triazole, pharmaceutical compositions thereof and their use in therapy)
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
CO5590926A2 (es) Uso de anastrozol para el tratamiento de mujeres posmenopausicas que tienen cancer precoz de mama
ES2078838A1 (es) Procedimiento para preparar una composicion a base de clozapina.
Balon Sildenafil and sexual dysfunction associated with antidepressants
JP2004529850A5 (es)
TH65931A3 (th) ยาสำหรับหญิงที่เสื่อมสมรรถภาพทางเพศและวิธีการใช้
CO5650242A2 (es) Metodo para tratar hipotiroidismo
ES2285865T3 (es) Utilizacion de una combinacion de una purina y un agente donador de monoxido de nitrogeno para prevenir o tratar disfunciones sexuales.
ECSP992843A (es) Procedimiento para aminorar la disfuncion sexual femenina
AU1972492A (en) Use of atipamezole for the treatment of male sexual impotence
RU2001124402A (ru) Гепатозащитное лекарственное средство
CO4340678A1 (es) Formulaciones para agentes farmaceuticos administrados en forma oral
BG106892U (en) Liquid medicamentous form
PE20040204A1 (es) Administracion de agentes para el tratamiento de la inflamacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal